X

Trial Profile

A Clinical Study to Evaluate Use of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in the Treatment of Adult COVID-19 Patients

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 28 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ischaemia-tolerant mesenchymal stem cells (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Expanded access; Proof of concept; Therapeutic Use

Most Recent Events

24 May 2021 According to Stemedica Cell Technologies media release, trial enrolled 14 critically ill COVID-19 patients in the study at the Providence Saint John's Health Center (Santa Monica, CA) and ProMedica (Toledo, OH).
04 Aug 2020 New trial record
28 Jul 2020 Results presented in a Stemedica Cell Technologies media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com